|
INHIBITOR -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
AGONIST -> TARGET
|
enhanced-affinity glucocorticoid
AGONIST
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
Selective Nonsteroidal Glucocorticoid Receptor Modulator
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
AGONIST -> TARGET
|
BINDING
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
0.45 NANOMOLAR [0.38 to 0.52] (average)
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
BINDING
|
|
MODULATOR->TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
LPS-induced TNF-α release in peripheral blood mononuclear cells. Efficacy, maximum response relative to Dexamethasone (100%)=75%
|
|
PARTIAL AGONIST->TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
BINDING
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
Luciferase transactivation assay in CV-1 (African green monkey kidney) cells transfected with hGR.alpha. expression vectors
AGONIST
4.37 NANOMOLAR (average) Emax = 1.28
|
|
INHIBITOR -> TARGET
|
BINDING
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
PARTIAL AGONIST->TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
AGONIST -> TARGET
|
BINDING
|
|
RADIOLIGAND->TARGET
|
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
AGONIST -> TARGET
|
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
6β-OH-21-desDFZ exhibited minimal binding to the human glucocorticoid receptor (<15%) at concentration up to 1 μM.
[>1] MICROMOLAR (average)
|
|
INHIBITOR -> TARGET
|
|
|
INHIBITOR -> TARGET
|
BINDING
1.736 MICROMOLAR (average)
|